Palantir Is Down 26% in 2026. The Fundamentals Are Going the Other Way.
PLTR posted 85% revenue growth in Q1. The stock keeps falling anyway. Here’s what the valuation math, the analyst divide, and the NHS risk actually mean for traders right now.
2026
The Metal Everything Runs On
Copper hit all-time highs in 2026. The miners haven’t fully priced what comes next.
The Warehouse Robot That Just Turned Profitable
Symbotic is no longer a story stock. The numbers are starting to say something different.
The Fed Has a New Chair. Markets Are About to Find Out What That Means.
Kevin Warsh’s first FOMC press conference is today. The rate decision isn’t the story — the tone is.
The Oil Trade Nobody Wanted — Until Now
Occidental Petroleum is up 38% in 2026. The setup behind it may have more room to run than the headlines suggest.
Crypto Stocks Are on Sale. That Doesn’t Mean the Story Broke.
Bitcoin hit $126K in October 2025. Now it’s in the $60Ks. COIN, MSTR, and RIOT are trading like the cycle is over. It probably isn’t.
Broadcom’s $100 Billion AI Roadmap Is Now the Trade — Here’s What the Numbers Actually Say
AVGO just posted record revenue and a $30B+ backlog. The real question is what the market has already priced in.
The Oil Stock That’s Quietly Printing Cash While the Market Looks Elsewhere
Diamondback Energy is generating free cash flow that most tech companies would envy — and almost nobody is talking about it the right way.
ADBE Just Beat Estimates and Still Fell 6%. Here’s What the Options Market Is Telling You.
Record revenue, raised guidance, a CFO exit — and the stock drops. The setup is more interesting than the headline.
GSK Just Paid $10.6 Billion for This Precision Oncology Bet — Here’s What It Signals
The Nuvalent acquisition is the biggest biopharma deal of the week — and it’s rewriting the playbook for lung cancer investing.